cognition and function, page-12

think given the early part of the condition even if placebo had decline in symptoms , it may have been too little to monitor or garner any statistically significant data... if you look at Prana's presentations that map the disease, PBT2 was jumping in before any major decline happens... Perhaps the benefit, like the disease, requires more time ...

after time to absorb everything, i still believe PBT2 could be of benefit as imagine trial information we have received to date does not say anything to the contrary ... rather rubs out one of the biomarkers and still no definitive answer on cognition.


i also feel the share price drop was far too severe... i thought 45-60c is fair value for where we are at now and was stunned by the drop ... last time we were in the 20's we hadn't been exposed to much of the pre-clinical data letalone huntington confirmation, etc..

the only thing im afraid of is how this will trade before we get announcement on future funding and further reporting on Reach2HD and imagine trials later in the year..